|
US7981420B2
(en)
|
2000-12-22 |
2011-07-19 |
Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. |
Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201006485A
(en)
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CN102149825B
(zh)
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
|
MX2011010166A
(es)
*
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
|
BR112012004546A8
(pt)
|
2009-08-29 |
2017-12-05 |
Abbott Lab |
Terapêutica por proteínas ligantes dll4-ligantes
|
|
WO2011028811A2
(en)
*
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
BR112012008833A2
(pt)
*
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
MX2012006560A
(es)
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
|
KR101853278B1
(ko)
|
2010-03-02 |
2018-05-02 |
애브비 인코포레이티드 |
치료학적 ｄｌｌ４ 결합 단백질
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
EA201391248A1
(ru)
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
|
BR112013031762A2
(pt)
|
2011-06-16 |
2016-09-13 |
Novartis Ag |
proteínas solúveis para utilização como terapêuticos
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
US20130195871A1
(en)
*
|
2011-12-30 |
2013-08-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
EP3369746A1
(en)
|
2012-01-27 |
2018-09-05 |
AbbVie Deutschland GmbH & Co KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
CN103382223B
(zh)
*
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
US20130297023A1
(en)
*
|
2012-05-07 |
2013-11-07 |
Hee-Jeong Im Sampen |
Methods and Devices For Treating Intervertebral Disc Disease
|
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
|
US9535071B2
(en)
|
2012-09-07 |
2017-01-03 |
The Governors Of The University Of Alberta |
Methods and compositions for diagnosis of inflammatory liver disease
|
|
TW202037609A
(zh)
|
2012-11-01 |
2020-10-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
|
US9856319B2
(en)
|
2012-12-28 |
2018-01-02 |
Abbvie Inc. |
Monovalent binding proteins
|
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
|
EP2968589A1
(en)
*
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Antibody drug conjugate (adc) purification
|
|
CN105722859B
(zh)
|
2013-07-25 |
2021-05-07 |
西托姆克斯治疗公司 |
多特异性抗体、多特异性可活化抗体及其使用方法
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
DK3078744T3
(da)
|
2013-12-04 |
2020-09-28 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
ES2792682T3
(es)
|
2014-02-10 |
2020-11-11 |
Respivant Sciences Gmbh |
Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
|
|
PL3104853T3
(pl)
|
2014-02-10 |
2020-05-18 |
Respivant Sciences Gmbh |
Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
WO2016073791A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
US10238625B2
(en)
|
2015-08-07 |
2019-03-26 |
Respivant Sciences Gmbh |
Methods for the treatment of mast cell related disorders with mast cell stabilizers
|
|
WO2017027402A1
(en)
|
2015-08-07 |
2017-02-16 |
Patara Pharma, LLC |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
PE20231050A1
(es)
|
2016-03-02 |
2023-07-11 |
Eisai Randd Man Co Ltd |
Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
WO2018044942A1
(en)
|
2016-08-31 |
2018-03-08 |
Patara Pharma, LLC |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
|
EP3522983A4
(en)
|
2016-10-07 |
2020-06-03 |
Respivant Sciences GmbH |
CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS
|
|
CN111356700A
(zh)
|
2017-09-08 |
2020-06-30 |
马弗里克治疗公司 |
受约束的条件性活化的结合蛋白
|
|
EP3758737A4
(en)
|
2018-03-02 |
2022-10-12 |
Kodiak Sciences Inc. |
IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
|
|
KR102259473B1
(ko)
|
2018-08-10 |
2021-06-02 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
WO2020232247A1
(en)
|
2019-05-14 |
2020-11-19 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
US12410238B2
(en)
|
2019-06-19 |
2025-09-09 |
Icahn School Of Medicine At Mount Sinai |
Monoclonal antibodies against JC virus
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3168986A1
(en)
|
2020-02-26 |
2021-09-02 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
US11338016B2
(en)
|
2020-05-20 |
2022-05-24 |
Howard University |
C-terminal fragment of tetanus toxin (Hc) for treatment of depression
|
|
IL298999A
(en)
|
2020-06-11 |
2023-02-01 |
Provention Bio Inc |
Methods and compositions for the prevention of type 1 diabetes
|
|
US20220267450A1
(en)
|
2020-10-14 |
2022-08-25 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
AU2021400284A1
(en)
*
|
2020-12-15 |
2023-06-22 |
Bicara Therapeutics Inc. |
Pharmaceutical formulations for fusion proteins
|
|
CN113234165B
(zh)
*
|
2021-05-07 |
2023-02-28 |
暨南大学 |
EpCAM的改造的结合蛋白及其应用
|
|
CN113354715B
(zh)
*
|
2021-05-07 |
2023-03-17 |
暨南大学 |
Egfr的改造的结合蛋白及其应用
|
|
JP2024520444A
(ja)
|
2021-05-24 |
2024-05-24 |
プロヴェンション・バイオ・インコーポレイテッド |
１型糖尿病を治療するための方法
|
|
EP4384219A4
(en)
|
2021-08-10 |
2025-06-18 |
Viridian Therapeutics, Inc. |
COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
|
|
WO2023083381A1
(zh)
|
2021-11-15 |
2023-05-19 |
成都百利多特生物药业有限责任公司 |
双特异性抗体-喜树碱类药物偶联物及其医药用途
|